c***m
发帖数: 2630 | | c***m
发帖数: 2630 | 2 这是原因-：
by seeking alpha Nov 21,2010
Bristol-Myers Squibb (BMY) and Pfizer (PFE) said they have discontinued the
late-stage clinical trial of their experimental antiplatelet drug apixaban
in patients with recent Acute Coronary Syndrome on the recommendation of an
independent data monitoring committee because of bleeding among patients
randomized to apixaban. This increase in bleeding was not offset by
clinically meaningful reductions in ischemic events. Enrollment will be
stopped and patients will be taken off of the study drug. The lead
investigators will complete a full evaluation of the available data set and
the results will be made public. The companies are moving forward with
apixaban in other indications. “Our recommendation to discontinue [the
study] concerns only the population of high-risk ACS patients receiving anti
-platelet therapy enrolled in [the study],” said Robert Harrington, Duke
Clinical Research Institute, and co-chair of the study steering committee. |
|
